Login / Signup

A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.

Céline LouapreMichelle RosenzwajgM GolseA RouxF PitoisetL AddaN TchitchekC PapeixE MaillartA UngureanuF Charbonnier-BeaupelD GalanaudJ C CorvolE VicautC LubetzkiDavid Klatzmann
Published in: Journal of neurology (2023)
ClinicalTrials.gov: NCT02424396; EU Clinical trials Register: 2014-000088-42.
Keyphrases
  • multiple sclerosis
  • double blind
  • clinical trial
  • low dose
  • placebo controlled
  • phase ii
  • high dose
  • phase iii
  • white matter
  • study protocol
  • randomized controlled trial
  • rheumatoid arthritis
  • systemic lupus erythematosus